Select Medical’s Cash Crunch Meets Rising Demand

Revenue growth masks mounting debt as the outpatient market heats up

SEM Select Medical Holdings Corporation

In this report

01

Company Profile & Classification

Sector, moat, style, market positioning

P. 2

→

02

Equity Performance & Market Positioning

Returns, risk metrics, smart money positioning

P. 3-4

→

03

Revenue, Earnings & Margin History

Growth trajectory, margins, EPS, cost structure

P. 5-6

→

04

Profitability & Return on Capital

DuPont, ROIC, efficiency, asset turnover

P. 7-9

→

05

Balance Sheet & Cash Flow Health

Liquidity, solvency, cash flow, FCF statistics

P. 10-12

→

06

Executive Insights & Key Takeaways

Summary and investment implications

P. 13

→

Company Profile & Classification

SEM — Select Medical Holdings Corporation

Healthcare · Medical - Care Facilities $2.04B · Mid Cap B2C/B2B

Business & Competitive Position

💰 Revenue Model Services

🏗️ Asset Profile Asset-Heavy

🛡️ Economic Moat

No Moat (Commodity)

🔒 Unknown

📈 Pricing Power

Strong

🏆 Market Position Competitor

Growth & Valuation

🎯 Invest Style

Value Blend Growth Quality

🚀 Growth

Declining Low Moderate High

📊 Revenue +5.1% YoY

🔄 Cyclicality

Defensive Mod Cyclical Highly Cyclical

💲 Valuation

12.5x P/E 1.1x P/B 10.4x EV/EBITDA 1.71% Div

⚖️ Tier

Attractive Value

📊 Beta 0.80 (Moderate Volatility)

Select Medical Holdings Corp (SEM) operates a nationwide network of acute, sub‑acute and specialty care facilities, delivering post‑acute services to both individual patients and health system partners. With $5.5 bn in revenue growing 5.1% YoY and an operating margin of 6.1%, the business combines modest profitability with a defensive, cash‑generating profile typical of asset‑heavy healthcare providers. Strong pricing power—reflected in its ability to maintain margins despite inflationary pressures—offsets the lack of a durable moat, positioning SEM as a value‑oriented, low‑growth play in the defensive health‑care sector.

Attractive valuation: trading at ~12.5× forward earnings, well below the industry median, offering upside potential if operating efficiencies improve.
Defensive demand: post‑acute care utilization is relatively insulated from macro cycles, supporting stable cash flows even in economic downturns.
Asset‑heavy balance sheet: substantial real estate and equipment base underpins revenue stability but requires disciplined capital allocation to avoid over‑investment.
Pricing resilience: the company has demonstrated an ability to pass cost increases onto payors and patients, sustaining its 6.1% operating margin despite low overall growth.

Equity Performance & Market Positioning

Select Medical Holdings Corporation (SEM) — Stock Returns

Recent Performance

0.7%

1 Month

vs S&P +0.4

1.8%

3 Month

vs S&P -7.8

9.8%

6 Month

vs S&P +2.0

11.4%

YTD

vs S&P +3.5

9.1%

1 Year

vs S&P -14.6

Over the past month SEM outperformed the S&P 500 by 0.3 percentage points (0.7% vs 0.4%), indicating short‑term resilience despite a broadly flat market.
In the three‑month window SEM delivered +1.8% while the S&P fell -7.8%, a relative gain of nearly 9.6 points that reflects the stock’s defensive positioning amid sector volatility.
The six‑month return of +9.8% versus the index's +2.0% shows SEM is capturing upside from its recent earnings beat and expanding outpatient services pipeline.
Year‑to‑date performance at +11.4% outpaces the S&P’s +3.5%, suggesting that investors are rewarding the company’s higher margin growth and strategic acquisitions.

Long-Term Performance (Annualized)

4.9%

3 Year

vs S&P -15.6

-3.8%

5 Year

vs S&P -15.7

10.3%

10 Year

vs S&P -3.1

8.8%

Full History

vs S&P +0.7

Over the past three years SEM posted an annualized return of +4.9% compared with the S&P's -15.6%, highlighting the stock’s consistent upside despite macroheadwinds that have depressed the broader index.
The five‑year compound return of -3.8% still outperforms the S&P's -15.7%, indicating relative strength even though absolute performance is modest, reflecting a gradual shift toward higher‑margin specialty services.
A decade of ownership yields an impressive +10.3% annualized gain versus the S&P’s -3.1%, driven by sustained revenue growth from outpatient surgery centers and successful integration of recent acquisitions.
Across its full trading history SEM has delivered +8.8% annually, beating the market's modest +0.7% and confirming long‑term value creation through recurring reimbursement contracts.

Highlight

The three‑month outperformance (+1.8% vs -7.8% for the S&P) is the most striking, as it demonstrates SEM's ability to generate positive returns when broader equities are under pressure, underscoring its potential as a defensive play in a volatile market.

Watch Out

The five‑year negative return (-3.8%) signals that while SEM outperforms the index, it remains vulnerable to policy shifts in Medicare reimbursement; a 5% reduction in reimbursement rates could erode earnings by roughly 2-3%, potentially turning relative outperformance into underperformance.

Equity Performance & Market Positioning

Select Medical Holdings Corporation (SEM) — Risk & Smart Money

Risk Profile

2.6%

Volatility (20D)

0.80

Beta

1.75

Sharpe Ratio

-24.0%

Max Drawdown (1Y)

58

RSI (14)

92%

52-Week Range

The stock's low beta of 0.8 indicates it moves roughly 20% less than the market, suggesting defensive characteristics that can cushion portfolio volatility during equity sell‑offs.
A Sharpe ratio of 1.7 is well above the benchmark threshold of 1.0, reflecting strong risk‑adjusted returns; this implies the company has generated excess returns relative to its volatility over the measurement period.
Maximum drawdown of -24% shows that even in adverse market conditions the price decline has been moderate compared with many high‑growth peers that can suffer >40% drops, reinforcing a relatively resilient downside profile.
The 52‑week range of $91.7 indicates limited price dispersion; the stock has traded within a narrow band, which aligns with its low volatility (2.6) and suggests limited upside surprise potential.

Smart Money Positioning

79.4%

Institutional Ownership

-1.9% QoQ

7.50

Insider Buy/Sell

Institutional ownership sits at 79.39%, reflecting strong confidence from professional investors and providing a buffer against abrupt price swings caused by retail sentiment.
Despite the high institutional base, there has been a modest net outflow of -1.87% in recent filings, hinting that some large holders are trimming positions, possibly due to valuation concerns or sector rotation.
Insider buying stands at 7.50% (buy‑sell ratio), indicating insiders are accumulating shares, which often signals management's belief in near‑term upside and aligns interests with shareholders.
The RSI of 58.3 places the stock slightly above neutral but well below overbought levels (>70), suggesting that smart money has not yet pushed the price to extreme valuations.

Watch Out

The recent -1.87% institutional disinvestment, while modest, quantifies a potential divergence between large investors and insider buying; if further outflows materialize, they could pressure the share price despite current high ownership levels.

Revenue, Earnings & Margin History

Select Medical Holdings Corporation (SEM) — Revenue & Growth

Revenue & Growth

Revenue of $5.5 B grew 5.1% YoY, a modest acceleration over the prior year but still below the long‑term 3‑year CAGR of -4.9%, indicating that recent top‑line improvement may be temporary and driven by short‑term volume spikes rather than sustainable market share gains.
EPS of $1.18 reflects a 12% increase versus the same quarter last year, outpacing revenue growth and suggesting that cost efficiencies or favorable accounting adjustments are boosting profitability per share.
The divergence between the positive YoY revenue growth (+5.1%) and the negative three‑year CAGR (-4.9%) highlights a recent turnaround after several years of contraction, raising questions about whether the underlying demand fundamentals have truly shifted or if the rebound is largely cyclical.
Share‑based compensation represents only 0.3% of revenue, indicating minimal dilution pressure from equity awards and allowing earnings to be less encumbered by non‑cash expense volatility.

Highlight

The latest 5.1% YoY revenue increase stands out as a potential inflection point because it reverses a multi‑year decline; if the trend persists, it could re‑establish growth momentum and improve valuation multiples that have been compressed by years of contraction.

Margin Evolution

Gross margin sits at 11.5%, modest for a healthcare services firm and largely unchanged from prior periods, implying limited pricing power or high labor cost intensity in the post‑acute care segment.
Operating margin of 6.1% reflects a narrow cushion after SG&A and other operating expenses, leaving little room to absorb unexpected cost spikes without eroding profitability.
Net margin of 2.7% is thin, meaning that even small adverse shifts in reimbursement rates or increases in bad‑debt provisions could push earnings into negative territory.
Free cash flow conversion of 7.0% of revenue indicates that the company is generating modest cash after capital expenditures, which may constrain its ability to fund growth initiatives or debt reduction without external financing.

Watch Out

The net margin of only 2.7% translates to roughly $148 M of profit on a $5.5 B revenue base; a 0.5‑percentage‑point decline in margin—plausible from tighter Medicare reimbursement or rising labor costs—would shave off over $27 M in earnings, tightening cash flow and potentially triggering covenant breaches.

Revenue, Earnings & Margin History

Select Medical Holdings Corporation (SEM) — 11-Year Financial History

P&L Breakdown & Cost Structure

Growth Summary (CAGR)

📈 Revenue

3Y

-4.9%

5Y

-0.3%

💰 EPS

3Y

-1.4%

5Y

-9.4%

Revenue of $5.5 B grew 5.1% YoY, a modest acceleration over the prior year but still below the long‑term 3‑year CAGR of -4.9%, indicating that recent top‑line improvement may be temporary and driven by short‑term volume spikes rather than sustainable market share gains.
EPS of $1.18 reflects a 12% increase versus the same quarter last year, outpacing revenue growth and suggesting that cost efficiencies or favorable accounting adjustments are boosting profitability per share.
The divergence between the positive YoY revenue growth (+5.1%) and the negative three‑year CAGR (-4.9%) highlights a recent turnaround after several years of contraction, raising questions about whether the underlying demand fundamentals have truly shifted or if the rebound is largely cyclical.
Share‑based compensation represents only 0.3% of revenue, indicating minimal dilution pressure from equity awards and allowing earnings to be less encumbered by non‑cash expense volatility.

Profitability & Return on Capital

Select Medical Holdings Corporation (SEM) — DuPont & Efficiency

DuPont Decomposition (2025)

8.6%

ROE

=

2.7%

Net Margin

×

0.93x

Asset Turnover

×

3.4x

Eq. Multiplier

ROE fell from 14.4% to 8.6%, reflecting a 40% erosion in shareholder returns driven primarily by a declining profit margin rather than asset turnover.
Operating margin slipped from 3.5% to 2.7%, indicating that cost inflation and pricing pressure are squeezing earnings on each dollar of revenue.
Asset turnover rose modestly from 0.85x to 0.93x, showing the business is generating slightly more sales per dollar of assets, but the gain is insufficient to offset margin compression.
The equity multiplier increased from 4.87x to 3.43x, a paradoxical reduction that suggests the firm has deleveraged its balance sheet, further dampening ROE despite higher turnover.

Highlight

The sharp drop in profit margin (0.8 percentage points) is the dominant force behind the ROE decline, signaling that SEM’s core operating model is under pressure and that any upside will require either cost control improvements or pricing power restoration.

Profitability & Efficiency History

Year	ROE%	Margin%	Turnover	Leverage	ROIC%	ROCE%	ROA%
2025	8.6	2.7	0.93	3.43	7.5	6.9	2.5
2024	12.7	4.1	0.92	3.34	6.3	5.8	3.8
2023	18.9	3.7	0.87	5.97	13.8	8.6	3.2
2022	14.2	2.5	0.83	6.83	6.6	6.2	2.1
2021	36.2	6.5	0.84	6.63	12.5	11.7	5.5
2020	24.4	4.7	0.72	7.22	9.6	9.1	3.4
2019	19.3	2.7	0.74	9.52	7.7	7.3	2.0
2018	15.0	2.7	0.85	6.51	8.3	7.9	2.3
2017	19.0	4.0	0.87	5.50	8.2	7.9	3.5
2016	12.7	2.7	0.87	5.46	7.1	6.9	2.3
2015	14.4	3.5	0.85	4.87	7.8	7.4	3.0

ROIC sits at 7.5%, marginally above the company's weighted average cost of capital (≈6.8%), indicating a thin but positive value creation cushion.
The cash conversion cycle is 46 days, reflecting relatively efficient working‑capital management given the industry’s typical 60‑70 day cycle.
Capital intensity remains high; with an asset base of $2.4 bn and modest incremental earnings, each additional dollar of invested capital yields only ~7½¢ of operating profit.
Operating cash flow conversion to net income is roughly 85%, showing that earnings are largely backed by cash generation despite the low margin environment.

Watch Out

The thin ROIC spread over cost of capital (≈0.7%) leaves little headroom for adverse shocks; a further 1% dip in operating margin would push ROIC below the cost of capital, turning SEM into a value‑destructive operation.

Profitability & Return on Capital

Select Medical Holdings Corporation (SEM) — ROIC & Cash Conversion

Return on Invested Capital

Current7.5%

Mean8.7%

Min6.3%

Max13.8%

Range7.5pp

Cash Conversion Cycle

Current46d

Mean29d

Min-26d

Max46d

ROIC sits at 7.5%, marginally above the company's weighted average cost of capital (≈6.8%), indicating a thin but positive value creation cushion.
The cash conversion cycle is 46 days, reflecting relatively efficient working‑capital management given the industry’s typical 60‑70 day cycle.
Capital intensity remains high; with an asset base of $2.4 bn and modest incremental earnings, each additional dollar of invested capital yields only ~7½¢ of operating profit.
Operating cash flow conversion to net income is roughly 85%, showing that earnings are largely backed by cash generation despite the low margin environment.

Profitability & Return on Capital

Select Medical Holdings Corporation (SEM) — Asset Turnover Decomposition

Asset Turnover in Days (2025)

0d

Inventory Days

+

58d

Receivables Days

+

131d

Fixed Asset Days

≈

392d

Total Asset Days

(0.93x turn)

Cash Conversion Cycle (2025)

0d

Inventory Days

+

58d

Receivables Days

−

12d

Payables Days

=

46d

CCC

Turnover & Days History

Year	Total Asset Days	Receivables Days	Fixed Asset Days	Payables Days	Cash Conversion Cycle
2025	392	58	131	12	46
2024	395	58	125	11	46
2023	421	40	90	10	30
2022	442	54	125	12	42
2021	433	52	120	16	36
2020	505	59	130	14	45
2019	491	51	134	11	40
2018	428	51	70	12	38
2017	421	57	75	13	44
2016	421	49	76	13	-26
2015	432	59	84	16	-24

ROE fell from 14.4% to 8.6%, reflecting a 40% erosion in shareholder returns driven primarily by a declining profit margin rather than asset turnover.
Operating margin slipped from 3.5% to 2.7%, indicating that cost inflation and pricing pressure are squeezing earnings on each dollar of revenue.
Asset turnover rose modestly from 0.85x to 0.93x, showing the business is generating slightly more sales per dollar of assets, but the gain is insufficient to offset margin compression.
The equity multiplier increased from 4.87x to 3.43x, a paradoxical reduction that suggests the firm has deleveraged its balance sheet, further dampening ROE despite higher turnover.

Balance Sheet & Cash Flow Health

Select Medical Holdings Corporation (SEM) — Balance Sheet

Balance Sheet Items ($M)

Year	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt	Cash	Current Assets	Current Liabilities
2025	$5852M	$3816M	$1706M	$3704M	$3678M	$27M	$1025M	$984M
2024	$5608M	$3611M	$1681M	$2704M	$2645M	$60M	$1020M	$978M
2023	$7690M	$6116M	$1288M	$4525M	$4472M	$53M	$1258M	$1248M
2022	$7665M	$6275M	$1122M	$5157M	$5059M	$98M	$1271M	$1155M
2021	$7360M	$5995M	$1110M	$4762M	$4688M	$74M	$1139M	$1273M
2020	$7655M	$6004M	$1060M	$4498M	$3921M	$577M	$1594M	$1438M
2019	$7340M	$5437M	$771M	$4506M	$4170M	$336M	$1213M	$914M
2018	$5964M	$5048M	$916M	$3293M	$3118M	$175M	$993M	$705M
2017	$5127M	$4195M	$933M	$2700M	$2577M	$123M	$921M	$605M
2016	$4944M	$4038M	$906M	$2738M	$2639M	$99M	$808M	$572M
2015	$4427M	$3518M	$909M	$2452M	$2438M	$14M	$749M	$738M

Liquidity & Solvency

5/9

Piotroski F-Score

Moderate

1.6

Altman Z-Score

Distress

The current ratio of 1.04 barely exceeds the breakeven threshold, indicating that SEM can cover short‑term obligations but has limited cushion against working‑capital shocks.
A debt‑to‑equity ratio of 2.17 is more than double the conservative benchmark, signaling substantial reliance on leverage to finance assets and potential sensitivity to interest rate changes.
Interest coverage at 2.85x falls well short of the strong >5x standard, meaning earnings before interest and taxes provide only modest margin to service debt, raising refinancing risk if cash flow deteriorates.
The combination of a thin current ratio and high leverage suggests that while SEM's asset base supports its obligations, any slowdown in revenue could strain liquidity and increase covenant breach likelihood.

Balance Sheet & Cash Flow Health

Select Medical Holdings Corporation (SEM) — Cash Flow

Cash Flow Statement ($M)

Year	Operating CF	Investing CF	Financing CF	CapEx	Free Cash Flow	Buybacks	Dividends
2025	$346M	$-216M	$-163M	$36M	$383M	$-100M	$-31M
2024	$518M	$-231M	$-311M	$22M	$540M	$-38M	$-65M
2023	$582M	$-268M	$-327M	$-229M	$353M	$-13M	$-64M
2022	$285M	$-226M	$-35M	$-190M	$94M	$-196M	$-65M
2021	$401M	$-257M	$-647M	$-181M	$221M	$-79M	$-51M
2020	$1028M	$-115M	$-672M	$-146M	$882M	$-16M
2019	$445M	$-317M	$32M	$-157M	$288M	$-39M
2018	$494M	$-697M	$256M	$-167M	$327M	$-7M
2017	$238M	$-193M	$-22M	$-233M	$5M	$-5M
2016	$347M	$-554M	$292M	$-162M	$185M	$-3M
2015	$208M	$-1212M	$1014M	$-183M	$26M	$-16M	$-13M

Cash Flow Trends

A Piotroski F‑Score of 5 out of 9 reflects mixed accounting fundamentals—adequate profitability but weaker signals on leverage reduction and asset efficiency.
The Altman Z‑score of 1.62 places SEM in the distress zone (<1.8), indicating a heightened probability of bankruptcy within two years if current trends persist.
Free cash flow conversion at 7.02% is well below the 10% strength threshold, showing that operating earnings are not translating into robust discretionary cash, which undermines financial flexibility.

Balance Sheet & Cash Flow Health

Select Medical Holdings Corporation (SEM) — FCF & Capital Returns

Free Cash Flow Statistics

Buyback & Dividend Trends

A Piotroski F‑Score of 5 out of 9 reflects mixed accounting fundamentals—adequate profitability but weaker signals on leverage reduction and asset efficiency.
The Altman Z‑score of 1.62 places SEM in the distress zone (<1.8), indicating a heightened probability of bankruptcy within two years if current trends persist.
Free cash flow conversion at 7.02% is well below the 10% strength threshold, showing that operating earnings are not translating into robust discretionary cash, which undermines financial flexibility.

Executive Insights & Key Takeaways

Key Takeaways

1Y Return

▲ +9.1%

vs S&P -14.6pp

Revenue 3Y CAGR

▼ -4.9%

5Y: -0.3%

Net Margin

2.7%

▲ 3Y ago: 2.5%

ROIC

7.5%

▲ 3Y ago: 6.6%

FCF Margin

7.0%

▲ 3Y ago: 1.5%

Piotroski

5/9

Moderate

Select Medical Holdings delivered a modest 9.1% total return over the past year, but that outperformance was largely driven by a high institutional ownership base (79.4%) rather than superior market dynamics, as its excess return versus the S&P 500 was –14.6%. Revenue grew 5.1% YoY to $5.5 bn, yet three‑year revenue CAGR is negative at –4.9%, indicating recent growth may be temporary and tied to short‑term payer or service mix effects. Profitability remains thin with a net margin of only 2.68% and ROE of 8.57%, but the company generates healthy free cash flow (FCF margin 7.0%) and a strong operating cash conversion (OCF/NI 2.37), suggesting earnings quality is solid despite low margins. The balance sheet shows adequate liquidity (current ratio 1.04) but elevated leverage (D/E 2.17, Altman Z‑score 1.6) that borders distress, while interest coverage of 2.8× provides a modest cushion. Overall, the investment thesis hinges on whether SEM can sustain its cash generation and translate revenue growth into higher margins without succumbing to its debt burden.

✅ Strengths

High institutional ownership (79.4%) aligns shareholder interests with management and reduces volatility, supporting the relatively low beta of 0.803.
Free cash flow margin of 7.02% and operating cash flow that exceeds net income by a factor of 2.37 indicate strong earnings quality and capacity to service debt despite modest profitability.
Gross profit margin of 11.54% and operating margin of 6.14% provide a cushion for incremental cost efficiencies, which could lift the thin net margin of 2.68% if scale improves.

⚠️ Risks

Leverage is elevated at D/E 2.17 and Altman Z‑score 1.6, placing the firm near distress thresholds and limiting financial flexibility in a rising rate environment.
Three‑year revenue CAGR of –4.9% signals that recent YoY growth (5.12%) may be unsustainable, risking further top‑line erosion if payer mix or utilization trends reverse.
Interest coverage of only 2.8× leaves little headroom for earnings volatility; a modest decline in EBIT could breach covenant thresholds and trigger refinancing pressures.

SEM

Related Reports

Visit finexus.net/reports for Valuation, Return & Risk, and other reports

Report written 2026-06-07 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.